Alibaba Health Reports 13.2% Revenue Increase and 62.2% Rise in Net Profit for FY2025

Reuters
19 May
Alibaba Health Reports 13.2% Revenue Increase and 62.2% Rise in Net Profit for FY2025

Alibaba Health Information Technology Ltd. has announced its audited annual results for the fiscal year ended March 31, 2025. The company's total revenue reached RMB30,598.3 million, marking a 13.2% increase year-on-year. Net profit for the period rose significantly by 62.2% to RMB1,432.0 million. The adjusted net profit totaled RMB1,949.7 million, reflecting a 35.6% increase year-on-year, and the adjusted net profit margin improved from 5.3% to 6.4%. During the reporting period, Alibaba Health continued to see steady growth in its business operations, driven by advancements in the "Internet + Healthcare" industry. The company actively engaged in various sectors, including medical services management, primary health services, and health industry development, laying the groundwork for exploration in medical AI. The Tmall Healthcare Platform also contributed to the company's stable growth trajectory.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alibaba Health Information Technology Ltd. published the original content used to generate this news brief on May 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10